Ilatreotide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596974

CAS#: 119719-11-8

Description: Ilatreotide is an Amadori compound of octreotide.


Chemical Structure

img
Ilatreotide
CAS# 119719-11-8

Theoretical Analysis

MedKoo Cat#: 596974
Name: Ilatreotide
CAS#: 119719-11-8
Chemical Formula: C61H86N10O20S2
Exact Mass: 1342.5461
Molecular Weight: 1343.52
Elemental Analysis: C, 54.53; H, 6.45; N, 10.43; O, 23.82; S, 4.77

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ilatreotide; Sdz CO 611;

IUPAC/Chemical Name: (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-19-((R)-3-phenyl-2-((((2R,3S,4R,5R)-2,3,5-trihydroxy-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl)amino)propanamido)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

InChi Key: FYSDQQZUTAKKQX-CULBQIHKSA-N

InChi Code: 1S/C61H86N10O20S2/c1-31(74)42(25-72)68-58(86)44-29-93-92-28-43(69-54(82)39(21-33-13-5-3-6-14-33)64-30-61(88)52(80)51(45(76)27-89-61)91-60-50(79)49(78)48(77)46(26-73)90-60)57(85)66-40(22-34-15-7-4-8-16-34)55(83)67-41(23-35-24-63-37-18-10-9-17-36(35)37)56(84)65-38(19-11-12-20-62)53(81)71-47(32(2)75)59(87)70-44/h3-10,13-18,24,31-32,38-52,60,63-64,72-80,88H,11-12,19-23,25-30,62H2,1-2H3,(H,65,84)(H,66,85)(H,67,83)(H,68,86)(H,69,82)(H,70,87)(H,71,81)/t31-,32-,38+,39-,40+,41-,42-,43+,44+,45-,46-,47+,48-,49+,50-,51-,52+,60-,61-/m1/s1

SMILES Code: O[C@@H]([C@H](O)[C@H]1O)[C@@H](CO)O[C@@H]1O[C@H]([C@@H](CO2)O)[C@H](O)[C@@]2(O)CN[C@H](Cc3ccccc3)C(N[C@@H](CSSC[C@@H](C(N[C@H](CO)[C@H](O)C)=O)NC([C@H]([C@H](O)C)NC([C@H](CCCCN)NC4=O)=O)=O)C(N[C@@H](Cc5ccccc5)C(N[C@@H]4Cc6c[nH]c7ccccc67)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1343.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cuyle PJ, Engelen A, Moons V, Tollens T, Carton S. Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery. J Drug Assess. 2018 May 23;7(1):28-33. doi: 10.1080/21556660.2018.1467916. eCollection 2018. PubMed PMID: 29888099; PubMed Central PMCID: PMC5990955.

2: Woodmansee WW, Gordon MB, Molitch ME, Ioachimescu AG, Carver DW, Mirakhur B, Cox D, Salvatori R. Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine. 2018 May 16. doi: 10.1007/s12020-018-1615-3. [Epub ahead of print] PubMed PMID: 29767287.

3: Tena I, Gupta G, Tajahuerce M, Benavent M, Cifrián M, Falcon A, Fonfria M, Del Olmo M, Reboll R, Conde A, Moreno F, Balaguer J, Cañete A, Palasí R, Bello P, Marco A, Ponce JL, Merino JF, Llombart A, Sanchez A, Pacak K. Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clin Med Insights Oncol. 2018 Apr 9;12:1179554918763367. doi: 10.1177/1179554918763367. eCollection 2018. PubMed PMID: 29720885; PubMed Central PMCID: PMC5922490.

4: Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30443-8. doi: 10.1053/j.gastro.2018.04.010. [Epub ahead of print] PubMed PMID: 29655834.

5: Vitale G, Dicitore A, Sciammarella C, Di Molfetta S, Rubino M, Faggiano A, Colao A. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocr Relat Cancer. 2018 Jun;25(6):R351-R364. doi: 10.1530/ERC-18-0010. Epub 2018 Apr 11. Review. PubMed PMID: 29643113.

6: Fountas A, Chai ST, Ayuk J, Gittoes N, Chavda S, Karavitaki N. A rare challenging case of co-existent craniopharyngioma, acromegaly and squamous cell lung cancer. Endocrinol Diabetes Metab Case Rep. 2018 Mar 28;2018. pii: 18-0018. doi: 10.1530/EDM-18-0018. eCollection 2018. PubMed PMID: 29623208; PubMed Central PMCID: PMC5881427.

7: Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies. J Clin Endocrinol Metab. 2018 Mar 23. doi: 10.1210/jc.2017-02566. [Epub ahead of print] PubMed PMID: 29590371.

8: Paragliola RM, Salvatori R. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Front Endocrinol (Lausanne). 2018 Mar 7;9:78. doi: 10.3389/fendo.2018.00078. eCollection 2018. Review. PubMed PMID: 29563895; PubMed Central PMCID: PMC5845985.

9: Brizzi MP, La Salvia A, Tampellini M, Sonetto C, Volante M, Scagliotti GV. Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review. BMC Cancer. 2018 Mar 20;18(1):311. doi: 10.1186/s12885-018-4205-0. PubMed PMID: 29558899; PubMed Central PMCID: PMC5861646.

10: Fisher GA Jr, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI; ELECT Study Investigators. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. Endocr Pract. 2018 Mar;24(3):243-255. doi: 10.4158/EP172000.OR. PubMed PMID: 29547049.

11: Tadman M, Charlton P, Jafar-Mohammadi B, Talbot D, Grossman AB. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE. Endocr Pract. 2018 Feb;24(2):189-194. doi: 10.4158/EP-2017-0137. PubMed PMID: 29466059.

12: Blesl A, Krones E, Pollheimer MJ, Haybaeck J, Wiesspeiner U, Lipp RW, Kump P. Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology? Case Rep Oncol. 2017 Dec 20;10(3):1121-1126. doi: 10.1159/000484473. eCollection 2017 Sep-Dec. PubMed PMID: 29430237; PubMed Central PMCID: PMC5803685.

13: Aerts M, Reynaert H. Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. Case Rep Gastroenterol. 2017 Dec 6;11(3):616-623. doi: 10.1159/000485025. eCollection 2017 Sep-Dec. PubMed PMID: 29430219; PubMed Central PMCID: PMC5803728.

14: Perrier ND. From Initial Description by Wermer to Present-Day MEN1: What have We Learned? World J Surg. 2018 Apr;42(4):1031-1035. doi: 10.1007/s00268-017-4435-3. PubMed PMID: 29383428.

15: Chicharro P, Paniagua A, Rodríguez-Jiménez P, Ibañes S, Cortina B, Riveiro J, Sampedro-Núñez MÁ, Fraga J, Marazuela M, Daudén E. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study. J Eur Acad Dermatol Venereol. 2018 Jan 29. doi: 10.1111/jdv.14830. [Epub ahead of print] PubMed PMID: 29377286.

16: Alquraini H, Del Pilar Schneider M, Mirakhur B, Barkan A. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials. Pituitary. 2018 Jun;21(3):283-289. doi: 10.1007/s11102-018-0867-5. PubMed PMID: 29357081.

17: Nguyen HT, Phung CD, Thapa RK, Pham TT, Tran TH, Jeong JH, Ku SK, Choi HG, Yong CS, Kim JO. Multifunctional nanoparticles as somatostatin receptor-targeting delivery system of polyaniline and methotrexate for combined chemo-photothermal therapy. Acta Biomater. 2018 Mar 1;68:154-167. doi: 10.1016/j.actbio.2017.12.033. Epub 2017 Dec 30. PubMed PMID: 29292170.

18: Wagner M, Samaha D, Khoury H, O'Neil WM, Lavoie L, Bennetts L, Badgley D, Gabriel S, Berthon A, Dolan J, Kulke MH, Goetghebeur M. Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. Adv Ther. 2018 Jan;35(1):81-99. doi: 10.1007/s12325-017-0653-1. Epub 2017 Dec 21. PubMed PMID: 29270780; PubMed Central PMCID: PMC5778190.

19: Teltayev D, Akshulakov S, Ryskeldiev N, Mustafin K, Vyacheslav L. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate. Gynecol Endocrinol. 2017;33(sup1):50-51. doi: 10.1080/09513590.2017.1404240. PubMed PMID: 29264984.

20: Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB 3rd. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors. Am Health Drug Benefits. 2017 Nov;10(8):408-415. PubMed PMID: 29263774; PubMed Central PMCID: PMC5726060.